Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Cubist Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Cubist Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cubist Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cubist Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cubist Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Cubist Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Cubist Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cubist Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cubist Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cubist Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cubist Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cubist Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Cubist Pharmaceuticals, Inc. Snapshot 6
Cubist Pharmaceuticals, Inc. Overview 6
Key Information 6
Key Facts 6
Cubist Pharmaceuticals, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
Cubist Pharmaceuticals, Inc. - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Combination Treatment Modalities 13
Pipeline Products - Partnered Products 14
Partnered Products/Combination Treatment Modalities 15
Cubist Pharmaceuticals, Inc. - Pipeline Products Glance 16
Cubist Pharmaceuticals, Inc. - Late Stage Pipeline Products 16
Pre-Registration Products/Combination Treatment Modalities 16
Phase III Products/Combination Treatment Modalities 17
Cubist Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Cubist Pharmaceuticals, Inc. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Cubist Pharmaceuticals, Inc. - Drug Profiles 22
(ceftolozane + tazobactam) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
tedizolid phosphate 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
bevenopran 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
fidaxomicin 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
solithromycin 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
surotomycin 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CB-618 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CB-027 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GP-4 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Inhibit DHFR for Bacterial Infections 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Bacterial Infections 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Undisclosed Drug Targeting GPCRs 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Cubist Pharmaceuticals, Inc. - Pipeline Analysis 40
Cubist Pharmaceuticals, Inc. - Pipeline Products by Target 40
Cubist Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 42
Cubist Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 43
Cubist Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 44
Cubist Pharmaceuticals, Inc. - Recent Pipeline Updates 46
Cubist Pharmaceuticals, Inc. - Dormant Projects 73
Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products 74
Discontinued Pipeline Product Profiles 74
(libivirumab + exbivirumab) 74
ADL-100101 74
ADL-5747 74
ADL-5859 74
CB-182804 74
CB-183872 75
CB-625 75
ecallantide 75
loperamide hydrochloride 75
Marine Natural Products Program 75
Cubist Pharmaceuticals, Inc. - Company Statement 76
Cubist Pharmaceuticals, Inc. - Locations And Subsidiaries 78
Head Office 78
Other Locations & Subsidiaries 78
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 81
Disclaimer 81

List of Tables
Cubist Pharmaceuticals, Inc., Key Information 6
Cubist Pharmaceuticals, Inc., Key Facts 6
Cubist Pharmaceuticals, Inc. - Pipeline by Indication, 2014 9
Cubist Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 11
Cubist Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 12
Cubist Pharmaceuticals, Inc. - Combination Treatment Modalities in Pipeline, 2014 13
Cubist Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2014 14
Cubist Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 15
Cubist Pharmaceuticals, Inc. - Pre-Registration, 2014 16
Cubist Pharmaceuticals, Inc. - Phase III, 2014 17
Cubist Pharmaceuticals, Inc. - Phase II, 2014 18
Cubist Pharmaceuticals, Inc. - Phase I, 2014 19
Cubist Pharmaceuticals, Inc. - Preclinical, 2014 20
Cubist Pharmaceuticals, Inc. - Discovery, 2014 21
Cubist Pharmaceuticals, Inc. - Pipeline by Target, 2014 41
Cubist Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 42
Cubist Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 43
Cubist Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 45
Cubist Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 46
Cubist Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 73
Cubist Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 74
Cubist Pharmaceuticals, Inc., Subsidiaries 78